- Home
- IPW vs INAB Comparison
IPW vs INAB Comparison
Compare IPW & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- INAB
- Stock Information
- Founded
- IPW 2018
- INAB 2016
- Country
- IPW United States
- INAB United States
- Employees
- IPW N/A
- INAB N/A
- Industry
- IPW Catalog/Specialty Distribution
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- INAB Health Care
- Exchange
- IPW Nasdaq
- INAB Nasdaq
- Market Cap
- IPW 22.6M
- INAB 23.5M
- IPO Year
- IPW 2021
- INAB 2021
- Fundamental
- Price
- IPW $0.72
- INAB $0.34
- Analyst Decision
- IPW Strong Buy
- INAB Strong Buy
- Analyst Count
- IPW 1
- INAB 3
- Target Price
- IPW $2.75
- INAB $7.75
- AVG Volume (30 Days)
- IPW 296.4K
- INAB 2.6M
- Earning Date
- IPW 11-14-2024
- INAB 11-12-2024
- Dividend Yield
- IPW N/A
- INAB N/A
- EPS Growth
- IPW N/A
- INAB N/A
- EPS
- IPW N/A
- INAB N/A
- Revenue
- IPW $78,571,632.00
- INAB N/A
- Revenue This Year
- IPW $8.31
- INAB N/A
- Revenue Next Year
- IPW $77.15
- INAB N/A
- P/E Ratio
- IPW N/A
- INAB N/A
- Revenue Growth
- IPW N/A
- INAB N/A
- 52 Week Low
- IPW $0.40
- INAB $0.22
- 52 Week High
- IPW $3.65
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- IPW 23.86
- INAB 52.90
- Support Level
- IPW $1.22
- INAB $0.30
- Resistance Level
- IPW $1.38
- INAB $0.37
- Average True Range (ATR)
- IPW 0.13
- INAB 0.05
- MACD
- IPW -0.05
- INAB 0.00
- Stochastic Oscillator
- IPW 0.91
- INAB 49.53
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.